Viking Therapeutics, Inc.

Organisation

9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121

Headquarters

Employees

Health Technology

Industry

Brian Lian

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Price

Target

Viking Therapeutics, Inc. (VKTX) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Viking Therapeutics, Inc. (VKTX) share price will touch around $92.72 in next 12-months.

Currently 17 wall-street analysts regularly analyze the financials of Viking Therapeutics, Inc. on a frequent basis to provide recommendations along with target share price. 17 analysts offering 12-month price forecasts for Viking Therapeutics, Inc. (VKTX) have a share price target of $92.72. This median of share price forecast represents a 179.45% upside from the latest price of $33.18 as on 27.03.26.

Viking Therapeutics, Inc. (VKTX) Share Price Forecast

Home

US Stocks

Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics, Inc. Stock Forecast

Viking Therapeutics, Inc. Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Viking Therapeutics, Inc. (VKTX): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Viking Therapeutics, Inc.'s share price and its median forecast price. As on 27.03.26, the difference is -63%

Viking Therapeutics, Inc. Forecast and Target Price

Viking Therapeutics, Inc. (VKTX) Share Price Forecast

Viking Therapeutics, Inc. (VKTX) Price vs Consensus Price Target

Viking Therapeutics, Inc. (VKTX) Share Price Forecast v/s Share Price Today

Viking Therapeutics, Inc. (VKTX): Difference between Current Price & Median Forecasted Price

Viking Therapeutics, Inc. (VKTX) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price